BACKGROUND: Intermittent androgen deprivation (IAD) for prostate cancer was studied with the objective of reducing the side effects of treatment and potentially delaying the development of hormone resistance. There also appears to be a quality of life benefit during off-treatment intervals owing to the recovery of serum testosterone levels. METHODS: In this multicentre European prospective randomised phase III trial EC507, testosterone serum concentrations were analysed in prostate cancer patients with PSA progression after radical prostatectomy. Patients were randomised to a continuous androgen deprivation (CAD) and IAD therapy using a 3-month depot with 11.25 mg leuprorelin acetate as microcapsule formulation. A complete IAD cycle comprises both a 6-month androgen deprivation therapy plus the off-treatment time (OTT). RESULTS: Serum testosterone recovery was recorded in 109 patients during OTT in the IAD group. Testosterone recovery to baseline values was achieved in 79.3% during the first and in 64.9% during the second IAD cycle, respectively. Median time to testosterone normalisation was 100 days in the first and 115 days in the second cycle, respectively. No significant difference was observed up to 1000 days between IAD and CAD with regard to time to androgen-independent progression. This is the first prospective study of leuprorelin acetate 11.25 mg demonstrating normalisation of testosterone levels in the off-treatment period in patients undergoing IAD. CONCLUSIONS: The prerequisite of an IAD treatment is the testosterone recovery during off-treatment periods. In this study, in patients with PSA relapse after radical prostatectomy, a real achievement of intermittent castration with normalisation of testosterone levels during off-treatment periods could be confirmed.
INTRODUCTION
The European Association of Urology Guidelines issued in 2010 state that for patients with pT x p N 1 disease who have PSA only recurrence following radical prostatectomy, androgen deprivation therapy (ADT) may help to delay progression and possibly achieve a survival benefit. 1 However, the advantages and disadvantages of continuous ADT need to be carefully balanced. One approach that aims to minimise the negative effects of therapy and maximise the benefits is an intermittent androgen deprivation (IAD) approach. IAD was initiated in prostate cancer patients after preclinical evidence showing that the use of hormonal therapy on an intermittent basis might delay hormonal resistance. 2, 3 Phase II studies have also indicated that IAD does provide a quality of life benefit during off-treatment intervals owing to the recovery of serum testosterone levels. 4, 5 A number of multi-institutional randomised trials on IAD are now ongoing and these should provide information on overall survival, time to develop androgen independence, quality of life benefits and reduction in the incidence of adverse effects. 4--6 The current European Association of Urology Guidelines state that IAD should no longer be regarded as investigational. 1 It has to be acknowledged that IAD should only be recommended for patients with PSA normalisation after a 6--9 month period of initial hormone deprivation. The German S3
Guidelines issued in 2009 also proposed IAD for prostate cancer patients, stating that they must be well-informed of the lack of long-term clinical data. 7 A prerequisite for an effective IAD strategy is the recovery of testosterone serum levels during off-treatment periods. There are a few publications available that show broad variations in percentage of patients achieving normalisation of testosterone and time to normalisation of testosterone concentrations in the off-treatment period. 8--11 Furthermore, different definitions of testosterone normalisation, different testosterone baseline values, varying lengths of hormone deprivation and different hormonal doses were applied giving major problems for a clear-cut definition of testosterone recovery in the off-treatment periods. This is the first report of an European multicentre, prospective phase III trial in patients with PSA progression after radical prostatectomy where serial serum testosterone concentrations were analysed to confirm that the dosage of 11.25 mg leuprorelin acetate microencapsulated as a 3-month depot (Trenantone, Enantone 11.25) results in a real intermittent castration with recovery and normalisation of testosterone serum levels in the offtreatment periods. Reported are the time to androgen-independent progression as well as the different patterns of testosterone recovery during the off-treatment periods in the IAD group. Quality of life, clinical and safety aspects of the continuous androgen deprivation-(CAD) and IAD-treated patients have been previously reported.
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MATERIALS AND METHODS
The study was a prospective, randomised, comparative, multicentre phase III clinical trial involving 86 centres in Germany and 12 centres in Italy, which commenced in January 1998 and had been completed in February 2005 (final report 2007). Included were men with systemic PSA progression (defined as a PSA level X1 ng ml À1 ) following an initial fall to o0.5 ng ml À1 within 3 months of radical prostatectomy. Men were required to have a testosterone value X100 ng dl À1 in order to rule out those with substantial hypogonadism and to allow for the effects of therapy on testosterone levels to be observed. At screening, all patients underwent mandatory clinical investigations comprising digital rectal examination, abdominal ultrasound, bone scintigram, as well as the optional examinations of liver ultrasound and chest X-ray. Staging was performed according to the Tumour Node Metastasis classification. 15 The overall study design is shown in Figure 1 . Patients underwent a 6-month androgen deprivation induction phase during which they received leuprorelin acetate as an 11.25 mg 3-month depot either by subcutaneous or intramuscular injection. Cyproterone acetate 200 mg per day orally was administered for the first 4 weeks to prevent tumour flare. Patients who achieved a PSA level o0.5 ng ml À1 at the end of the induction phase were randomised to one of the two arms: an IAD arm and a CAD arm. Patients in the CAD arm received CAD with leuprorelin acetate 11.25 mg 3-month depot until androgen-independent progression was observed. Androgenindependent progression was defined as a PSA level of X3 ng ml À1 on two consecutive months during a 6-month testosterone suppression despite castration levels of testosterone p50 ng dl
À1
. This level was chosen based on empirical evidence from phase II studies. 16 In the IAD, arm treatment was discontinued again if the PSA level fell to o0.5 ng ml À1 and there were no signs of clinical progression. A minimum of 6 months of treatment was required despite a quicker drop in PSA serum levels in order to regain apoptotic responsiveness. If after 6 months of treatment the PSA level was 40.5 ng ml À1 but p3 ng ml
, then the treatment was continued for another 3 months. If after a 9-month treatment period the PSA level was still 40.5 ng/ml, then the patient's participation in the study was terminated.
Serum PSA levels were measured at 3-month intervals in patients in the CAD arm and at 3-month intervals in patients in the IAD arm during the on-treatment phase and monthly during the off-treatment interval. PSA and testosterone measurements were performed in a central laboratory in Leverkusen (Prof. G. Horpacsy, German centres) and Milano (CDI Centro Diagnostico Italiano, Italian centres) (Appendix). Serum testosterone levels were determined using commercially available test kits; CHIRON/DIAG-NOSTICS ACS: 180 in Germany and ARCHITECT Testosterone, Abbott diagnostics in Italy. Both test kits are based on an immunoassay chemiluminescence technology. The comercially available E.I.A. Hybritech test kit was used for PSA measurements.
The primary confirmatory target variable of the study was androgenindependent tumour progression within 2 years. To calculate the time until androgen-independent progression, the log-rank test on non-inferiority was applied. The statistical analyses and generation of tables and patient data listings were performed using the statistical software package SAS version 8.2 at the computer facilities of Omnicare, CRO, Cologne, Germany.
RESULTS
Of the 244 patients enrolled in the study, 201 patients were randomised to treatment with IAD (n ¼ 109) and CAD (n ¼ 92) respectively; 33 patients did not meet the criterion for randomisation and 10 patients withdrew prematurely. At baseline, demographic data and tumour characteristics were well-balanced between treatment groups ( Table 1) .
The median time for androgen-independent tumour progression (set at 2 years, primary efficacy parameter) was not reached at study end. At day 1000, there were 16 patients in the CAD arm and 37 in the IAD arm who were at risk of progression. The mean (s.d.) time until androgen-independent progression showed no significant differences between treatment groups; 986 (10.0) and 976 (14.0) days in the CAD arm and the IAD arm, respectively ((P ¼ 0.853) using the log-rank test, intent to treat analysis set, secondary efficacy parameter). The Kaplan--Meier analysis of time until androgen-independent progression is shown in Figure 2 . The time until PSA progression was defined as the time between date of visit 0 and date of onset of PSA-progression (for cases with PSA progression), and date of last observation (for cases without PSA progression) respectively.
The individual testosterone courses were analysed in the 109 patients on IAD therapy. In all 109 patients, castration testosterone levels were achieved after 6 months of treatment involving two subcutaneous injections of the 3-month depot. A cycle was defined as the 6 months of ADT plus the off-treatment time (OTT). Patients with long IAD cycles X20 months showed, in most of clinical parameters, a statistically significant better outcome in comparison with those patients with a cycle length of p15 Abbreviations: BMI, body mass index; CAD, continuous androgen deprivation; IAD, intermittent androgen deprivation; ns, not significant; RPV, radical prostatectomy; sig., significant P values based on two-sided t-test or Fisher' s exact test (two-sided), respectively. months ( Table 2) . Achievement of testosterone baseline levels or lack thereof showed a trend for better outcome in time for clinical/PSA progression and time to PSA increase in those achieving baseline testosterone levels but reached no statistical significance.
Of the 82 patients completing cycle 1, normalisation of testosterone to X2.3 ng ml À1 was reported in 92.7% and among the 37 patients completing cycle 2, the equivalent proportion was 81.1%. Of note is that, a statistically significant correlation of testosterone normalisation could be shown in relation to the baseline testosterone levels in cycle 1 and 2, whereas age and body mass index seemed to be of no importance (Table 3) . Baseline testosterone levels were again reached in 79.3 and 64.9% of patients during OTT in those completing cycles 1 and 2, respectively. No baseline values were recorded in cycle 1 for three patients (3.7%).
In the first cycle, testosterone doubling time during OTT was 13--56 days with a more pronounced testosterone increase in the first month after stopping ADT. The median time for normalisation of testosterone to X2.3 ng ml À1 was 100 days in the first and 115 days in the second cycle respectively (Figure 3a) . Figure 3b illustrates testosterone recovery during OTT in cycles 1 and 2 by means of median values of testosterone concentrations of all patients. In patients with low normal-testosterone baseline values (2.3 to 4 ng ml À1 ), time for recovery was prolonged in comparison with those having high (44 ng ml À1 ) normal testosterone values (Figure 4 ). An overview of summary statistics of the outcome in the IAD patients is provided in Table 4 . Abbreviations: BMI, body mass index; n.s., not significant; sig., significant. P values based on two-sided t-test. 
DISCUSSION
ADT fails to eliminate the entire malignant-cell population and after a variable period of time the tumour relapses into an androgen-independent state of growth. Animal experimental data indicate that cyclical AD would delay the emergence of androgenindependence. 2 Therefore, IAD holds the potential of minimizing adverse events and improving the quality of life during OTT, while maintaining clinical anti-tumour effects and improving time to hormone refractory state. A key issue in this scenario is that the serum testosterone levels should recover during OTT to normal values with IAD leading to a real intermittent 'castration' (not just an intermittent treatment delivery).
Testosterone recovery after 6 months of IAD has been reported in a phase III clinical trial. 17, 18 Median baseline value of testosterone was 3.11 ng ml À1 and time for recovery of testosterone was 15.4 and 18.3 weeks in the first and second IAD cycles, respectively. As in the current study, among patients with low testosterone baseline-values time to testosterone normalisation was prolonged in comparison with those with normal testosterone baseline values. These data are in accordance with the findings of Gulley and coworkers, who showed that after 6 months of ADT with a gonadotropin-releasing hormone agonist the median time until testosterone normalisation was 16.6 weeks and could be achieved in more than 80% of the patients. 9, 10 In all the three studies by Gulley, Figg and Oefelein, 10, 18, 19 the higher dosage of leuprorelin acetate registered in the United States (3-month depot 22.5 mg) was administered whereas the time of androgen withdrawal with 3 months was different. 10, 19 IAD seems to be an option to balance benefits and disadvantages of ADT but should not interfere with the incidence of progression and mortality. 5, 6, 20, 21 In a recently published study, 1386 patients with PSA progression after radical radiotherapy with no evidence of distant metastases were randomised to one of the two treatment arms, IAD (n ¼ 690) or CAD (n ¼ 696) with a luteinising hormone-releasing hormone agonist plus an anti-androgen. 21 The IAD arm comprised an 8 months on-treatment period, which was reinstituted during the off-treatment interval if PSA levels reached 410 ng ml À1 . The primary endpoint of the study was overall survival and the secondary endpoints included time to hormone refractory state. The median follow-up of the study was 6.9 years. Median overall survival was 8.8 versus 9.1 years on IAD and CAD arms, respectively (hazard ratio 1.02; 95% confidence interval (CI): 0.86--1.21; P for non-inferiority (IAD versus CAD X1.25) ¼ 0.009). The IAD arm had more disease-related deaths but fewer unrelated deaths. Time to hormone refractory state was statistically significantly improved in the IAD arm (hazard ratio 0.80; 95% CI: 0.67--0.98; P ¼ 0.024). The study showed that in men with PSA recurrence after radical radiotherapy, IAD was non-inferior to CAD with respect to the overall survival. To date, phase III studies have shown that IAD is non-inferior to continuous AD. 11, 21 The current report in IAD is the first on testosterone recovery after a 6-month IAD treatment with the 11.25 mg 3-month depot microcapsule formulation of leuprorelin acetate. After ADT and induction of testosterone castration levels, median time to testosterone normalisation during OTT was 100 days in the first and 115 days in the second cycle. Normalisation of testosterone levels were achieved in 92.7 and 81.1% of patients in the first and second cycle, respectively. These findings indicate that a real intermittent castration was achieved with temporary suppression of the hypothalamic-pituitary-gonadal axis and reversibility during OTT with normalisation of testosterone values. The mean (s.d.) time until androgen-independent progression showed no significant differences between treatment groups with 986 (10.0 days) and 976 (14.0 days) days in the CAD and IAD arm, respectively.
Our study confirms that the IAD resulted in recovery of testosterone during the OTT, which is the prerequisite for the reversal of the adverse events due to CAD. Based on our findings, the individual testosterone baseline values were considered to be important and should be determined before IAD treatment starts and during OTT to estimate testosterone recovery.
CONCLUSION
This study with the 3-month 11.25 mg depot microcapsule formulation of leuprorelin acetate shows a real achievement of intermittent castration with normalisation of testosterone levels during off-treatment periods. It is assumed that the recovery of testosterone in IAD patients will balance the benefits of long-term androgen withdrawal and reduce ADT-related side effects. IAD seems to be a feasible option in selected well-informed and compliant patients who need long-term hormonal deprivation.
CONFLICT OF INTEREST
Professor Ulf Tunn is consultant and lecturer for Abbott, Astellas, Bayer Health, Novartis, Sanofi-Aventis and Takeda. Dr Giorgio Canepa and Dr Andreas 
